A newly discovered protein controls the switch that tells cells when to divide
Every cell in the body follows a tightly regulated cycle of growth and division. When that regulation breaks down, cancer follows.
Cell division is among the most studied processes in biology — yet major gaps remain. Each step in the so-called cell cycle is governed by a series of molecular switches. If those switches malfunction, a cell can divide without restraint, which is essentially what cancer is. Using the Cancer Dependency Map — a large database tracking which genes cancer cells rely on for survival — researchers identified a protein called FAM53C as a new and previously uncharacterised regulator of cell cycle progression. Specifically, it proved essential for the transition from the G1 phase to the S phase: the critical moment when a cell commits to copying its DNA and proceeding with division.
The G1/S transition is one of the most closely guarded checkpoints in cellular biology. Several cancer therapies already target proteins operating at this juncture — CDK4 and CDK6 inhibitors, for instance, are approved for certain breast cancers. FAM53C turns out to act upstream of another well-known protein, DYRK1A, which in turn influences this checkpoint. That positioning makes FAM53C a potentially valuable target for drug development.
The connection to aging
The cell cycle is not relevant to cancer alone. Cellular aging is closely tied to a phenomenon called senescence — a state in which cells stop dividing but also fail to die. Instead, they linger and release inflammatory signals that degrade surrounding tissue. This process is increasingly understood as a central driver of age-related diseases, from arthritis to cardiovascular conditions. The molecular machinery that determines whether a cell continues dividing or enters senescence is therefore directly relevant to the biology of aging itself.
FAM53C has barely been studied until now. Mapping its function opens immediate questions about its role beyond cancer: does it also influence the transition to senescence? Is its expression altered in aged tissue? These questions are logical next steps, but none have yet been answered.
From data to discovery
The methodological approach here is worth noting. Rather than starting with a known disease or a suspected gene, the researchers began with a large-scale dataset and let the statistics point toward the unknown. The Cancer Dependency Map spans hundreds of cancer cell types and can flag genes that are essential for cell survival even when nobody was looking for them. That data-first approach suggests there may be considerably more uncharted players in cell cycle regulation still waiting to be found.